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OBJECTIVEdAvailable evidence supports the emerging hypothesis that metabolic syndrome
may be associated with the risk of some common cancers. We did a systematic review and meta-
analysis to assess the association between metabolic syndrome and risk of cancer at different sites.
RESEARCHDESIGNANDMETHODSdWe conducted an electronic search for articles
published through October 2011 without restrictions and by reviewing reference lists from
retrieved articles. Every included study was to report risk estimates with 95% CIs for the asso-
ciation between metabolic syndrome and cancer.
RESULTSdWe analyzed 116 datasets from 43 articles, including 38,940 cases of cancer. In
cohort studies inmen, the presence of metabolic syndrome was associatedwith liver (relative risk
1.43, P, 0.0001), colorectal (1.25, P, 0.001), and bladder cancer (1.10, P = 0.013). In cohort
studies in women, the presence of metabolic syndrome was associated with endometrial (1.61,
P = 0.001), pancreatic (1.58, P, 0.0001), breast postmenopausal (1.56, P = 0.017), rectal (1.52,
P = 0.005), and colorectal (1.34, P = 0.006) cancers. Associations with metabolic syndrome were
stronger in women than in men for pancreatic (P = 0.01) and rectal (P = 0.01) cancers. Associ-
ations were different between ethnic groups: we recorded stronger associations in Asia popula-
tions for liver cancer (P = 0.002), in European populations for colorectal cancer in women
(P = 0.004), and in U.S. populations (whites) for prostate cancer (P = 0.001).
CONCLUSIONSdMetabolic syndrome is associated with increased risk of common cancers;
for some cancers, the risk differs betweens sexes, populations, and deﬁnitions of metabolic
syndrome.
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The metabolic syndrome is a clusterof risk factors for cardiovasculardisease and type 2 diabetes and
constitutes a growing problem world-
wide (1). These factors include obesity
(particularly central adiposity), dys-
glycemia, raised blood pressure, elevated
triglyceride levels, and low HDL choles-
terol levels. On the basis of the most re-
cent epidemiological analysis using the
American Heart Association/National
Heart, Lung, and Blood Institute 2005
guidelines, similar to those of National
Cholesterol Education Program/Adult
Treatment Panel III, slightly more than
one-third (35%) of adults in the U.S.
could be characterized as having the met-
abolic syndrome (1). This translates to
nearly 80 million U.S. adults affected by
the syndrome (calculated from U.S. Bu-
reau of the Census data for 2007, with an
adult resident population of 228 mil-
lion). A higher percentage (40.1%) of
prevalence occurred with revised Inter-
national Diabetes Federation 2005 crite-
ria, which use a lower cutoff point for
waist ($94 cm in men and $80 cm in
women).
Available evidence from epidemio-
logic investigations and experimental,
translational, and clinical studies sup-
ports the emerging hypothesis that met-
abolic syndrome may be an important
etiologic factor for the development and
progression of certain types of cancer and
also for overall cancer mortality (2). Dif-
ferences in the study populations, length
of follow-up, sample sizes, frequency of
events, study end points, and statistical
adjustment for confounding may all
have contributed to the conﬂicting pat-
terns of association seen in earlier stud-
ies. Moreover, both obesity (3) and
diabetes (4) have repeatedly been associ-
ated with increased incidence for some
common cancers, and both conditions
represent two important factors contrib-
uting to the prevalence of the metabolic
syndrome. There is also some evidence
that dyslipidemia (low HDL cholesterol
levels and/or raised triglyceride) is asso-
ciated with some cancers (5). It therefore
remains possible that some of the associ-
ations between metabolic syndrome and
cancer risk may be mediated by the co-
existence of obesity and overt diabetes.
A systematic and quantitative assess-
ment of published studies is not available.
Therefore, we conducted a meta-analysis
to summarize all published studies to date
on the incidence of cancer associated with
metabolic syndrome.
RESEARCH DESIGN AND
METHODS
Data sources
We followed the PRISMA (Preferred Re-
porting Items for Systematic reviews and
Meta-Analyses) checklist for reporting
systematic reviews and meta-analyses
(6). We systematically searched Medline,
Embase, CENTRAL, CINAHL, and Web
of Science through October 2011 for
studies in humans of the association be-
tween metabolic syndrome and cancer.
Our core search consisted of the termsmet-
abolic syndrome, insulin resistance syn-
drome, and syndrome X, combined with
speciﬁc terms for each cancer site: colorec-
tal (colon and rectum), gastric, esophageal,
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hepatobiliary (liver and gallbladder),
pancreas, lung, bladder, thyroid, renal,
leukemia, malignant melanoma, multiple
myeloma, and non-Hodgkin lymphoma
for both sexes and prostate, breast, ovary,
and endometrium for single sex. Relevant
journals, bibliographies, reviews, and
personal ﬁles were hand searched for ad-
ditional articles. The search had no lan-
guage restriction. The last search was
performed on 31 October 2011. The
electronic database search strategy for
Medline is available in Supplementary
Table 1.
Study selection
We included studies if 1) their aim was to
assess the effect ofmetabolic syndrome on
risk of cancer or association with cancer,
2) they reported the deﬁnition of meta-
bolic syndrome according to criteria of
national or international scientiﬁc associa-
tions, federations, or organizations (tradi-
tional deﬁnitions) or if they used proxy
indicators in the absence of the original
data (nontraditional deﬁnitions), and 3)
they included at least three factors, even in
the absence of others. We included cohort
studies, nested case-control studies, control
arms from clinical trials, case-control stud-
ies, patient series, andmortality studies.We
speciﬁed that every studymust either report
risk estimates (relative risks [RRs], odds ra-
tios, hazard ratios, and standardized inci-
dence ratio) with 95% CIs separately for
men, women, or both or must report sufﬁ-
cient data to estimate these. If a site-speciﬁc
dataset had been published more than
once, we used the most recent publication.
We included a speciﬁc cancer site in the
analysis if there were at least two cohort
datasets. We excluded studies that were
not published as full reports, such as con-
ference abstracts and letters to editors, and
studies of cancer precursors (e.g., colorectal
adenoma).
Data extraction
From each retrieved article, we extracted
the following data: name of the ﬁrst
author, year of publication, country
where the study was performed, speciﬁc
outcomes, follow-up time, proportion of
men and women, total number of indi-
viduals, number of cases, and risk esti-
mates and their 95% CIs (presence versus
absence of metabolic syndrome). We col-
lected data for the most adjusted model.
Populations were categorized into four
groups: U.S., Europe, Asia, and other.
Returned articles were reviewed against
inclusion and exclusion criteria by three
reviewers (D.G., K.E., and P.C.) until
interrater reliability (k$ 0.60) was estab-
lished. Methodological quality of each
study was assessed according to three
study components that might affect the
strength of the association between meta-
bolic syndrome and cancer risk: length of
follow-up for cohort studies, whether
metabolic syndrome deﬁnition was tradi-
tional or nontraditional, and the extent of
adjustments for potential confounding
factors.We also collected, where available,
risk estimates of the association with can-
cer for each single factor of the syndrome
taken at its highest level.
Data synthesis and analysis
The primary end point was to assess the
association between metabolic syndrome
and cancer risk in cohort studies. For the
main outcome at each cancer site, we
graded the evidence for study quality and
Table 1dBaseline characteristics of studies included in meta-analysis
Cancer sites
No. of
datasets*
Population group
No. of
cases in men
No.
of cases in
women
MS: traditional vs.
non-traditionalx Type of studiesU.S. Europe Asia Other
Colorectal 38 6 23 9 6,661 4,341 14 vs. 8
9 cohorts, 2 n-c/c,
1 RCT, 2 c/c
Colon 11 7 4 1,529 1,035
Rectum 11 7 4 1,035 647
Breast cancer 12 1 7 3 1, Brazil 9,643 5 vs. 4 4 cohorts, 1 RCT,
2 n-c/c, 2 c/c
Postmenopausal 7 1 4 2 5,161
Hepatobiliary 14 3 5 6 Total 5,580 M and F 5 vs. 5 5 cohorts, 2 c/c
Liver 10 3 3 4 3,199 1,758
Gallbladder 4 2 54 10
2 559 M and F
Prostate 14 4 8 2 4,623 6 vs. 5 10 cohorts, 1 n-c/c,
2 c/c, 1 series
Endometrium 5 4 1, Canada 2,190 2 cohorts, 1 n-c/c, 2 c/c
Pancreas 9 1 6 2 823 527 3 vs. 6 4 cohorts, 1 c/c
Gastric 7 1 2 4 506 309 4 cohorts
Lung 7 1 2 4 536 174 4 cohorts
Bladder 4 4 1641 337 4 cohorts
Thyroid 4 4 137 258 4 cohorts
Ovary 2 2 654 2 cohorts
Total 116 17 67 30 2 18,180† 20,010†
c/c, case-control; MS, metabolic syndrome; n-c/c, nested case-control; RCT, randomized controlled trial; traditional, diagnosis of MS made according to national and
international scientiﬁc associations. M, male. F, female. *Datasets refers to a site-speciﬁc group per article. Several articles reported multiple sites: each site counted as
one dataset; if an article reported separated analysis for sex or age at the same site, these were counted as two datasets. xAnalysis was performed for cohorts only when
numbers of datasets were nine or more. †Total n (both sexes) = 38,381 cases, to which must be added 559 cases for gallbladder cancer in both sexes (n = 38,940
cases).
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for the risk of bias: study quality was based
on the number of datasets, number of
events, width of CIs, and heterogeneity;
risk of bias was mainly based on type of
study and adjustment for confounders.
Unless otherwise stated, we used the most
adjusted risk estimate from each study.
Heterogeneity of the effect across studies
was assessed by Q2 statistics, which is
distributed as x2 statistics (7). A value
of P , 0.10 was used to indicate lack of
homogeneity (heterogeneity) among
effects. I2 statistics were provided to quan-
tify the percentage of total variation across
studies that was attributable to heteroge-
neity rather than to chance. I2 values of 25,
50, and 75% correspond to cutoff points
for low, moderate, and high degrees of
heterogeneity. We used a ﬁxed-effects
model if I2 value signiﬁcance was .0.1;
otherwise, we used a random-effect
model. We did subgroup analyses for
each site to identify study-level factors
that modify the association between the
presence of metabolic syndrome and can-
cer risk: these factors include sex, subsite
(e.g., colon and rectum), deﬁnition of
metabolic syndrome (traditional versus
nontraditional), and design; for incidence
of cancer, we considered cohort studies,
nested case-control studies, and control
arms of clinical trials. Sensitivity analyses
evaluated whether the results could have
been affected markedly by a single study
and were repeated using a ﬁxed-effects
model. Publication bias was examined in
funnel plots and with a regression asym-
metry test: the Egger test is best for cancer
sites with 10 or more datasets. We used
STATA, version 9.0 (STATA, College Sta-
tion, TX), to analyze data.
RESULTSdWe screened 2,628 poten-
tially relevant, nonduplicate articles. The
k score for concordance between review-
ers rating the articles was 0.62–0.77. The
ﬁnal number of articles (8–50) included
in the meta-analysis was 43 (Supplemen-
tary Fig. 1), which reported on 116 data-
sets (Supplementary Table 2). All articles
were published in English. The character-
istics of included studies are summarized
in Table 1 and Supplementary Table 3.
The analysis included 38,940 cancer cases
(18,180 men and 20,201 women, plus
559 cases for gallbladder cancer not di-
vided by sex). The median follow-up per
cohort studies and per cancer site varied
from 3 years (endometrium) to 12.2 years
(prostate). Notably, no North American
population data contributed to the sum-
maries for gallbladder, ovary, thyroid,
and bladder cancers. The proportion of
studies in which the deﬁnition of meta-
bolic syndrome was traditional varied by
cancer sites: higher for colorectal (14 vs. 8
nontraditional); approximately equal for
breast, hepatobiliary and prostate; and
lower for pancreas. No further differenti-
ation was made when the number of data-
sets for cancer site was four or fewer. The
number of potential confounding factors
(cancer-site–speciﬁc risk factors) in-
cluded in the adjusted analyses also
varied (Supplementary Table 3).
Fig. 1A and B shows the results of
meta-analyses of RR (for presence of meta-
bolic syndrome) in men and in women,
respectively, for cohort studies only. Sepa-
rate meta-analyses for some relevant sites
and for sex are given in Supplementary
Figs. 1–6. Inmen, the presence ofmetabolic
Figure 1dSummary risk estimates by cancer sites in men (A) and in women (B).
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syndrome was associated with liver (Fig. 2;
RR 1.43, P, 0.0001) and colorectal (Fig.
2A; 1.25, P , 0.001) cancers and weakly
associated with bladder cancer (1.10, P =
0.013). Between-study heterogeneity was
low or moderate for liver, colorectal, and
bladder cancer (I2 = 0.0, 35, and 0.0%,
respectively) (Fig. 1A). The quality of the
evidence was high for the association with
colorectal cancer (high number of datasets
and events, narrow CIs, and low hetero-
geneity), moderate for liver cancer, and
low for bladder cancer. The overall risk
of bias was low, as all studies were
prospective cohort studies and most ad-
justed for many confounders.
In women, the presence of metabolic
syndrome was associated with endo-
metrial (Fig. 2B; RR 1.61, P = 0.001), pan-
creas (Fig. 2B; 1.58, P , 0.0001), breast
postmenopausal (Fig. 2B; 1.56, P =
0.017), rectal (1.52, P = 0.005), and co-
lorectal (Fig. 2B; 1.34, P = 0.006) cancers;
the association with ovary cancer (1.26)
was of borderline signiﬁcance (P =
0.054). Between-study heterogeneity
was high for endometrial, breast post-
menopausal, and colorectal cancers and
moderate or low for rectal (I2 = 35%),
pancreas (0.0%), and ovary cancers
(8.8%) (Fig. 1B). The quality of the evi-
dence was moderate for the association
with colorectal and pancreas cancers
and low for endometrium and breast
postmenopausal cancers. The overall
risk of bias was low, as all studies were
prospective cohort studies and most ad-
justed for many confounders. Associa-
tions with metabolic syndrome were
stronger in women than in men for pan-
creas (P = 0.01), rectal (P = 0.01), and
bladder (P = 0.01) cancers.
We also examined whether estimates
varied between populations in cancer sites
for which we had at least two datasets from
the main geographical regions (Table 2).
For colorectal cancer, for example, we
recorded a positive association in U.S.
and Europe populations for men and in
Europe populations for women; for post-
menopausal breast cancer, the positive as-
sociation was lost in Europe populations;
for liver cancer, the association remained
signiﬁcant in Europe and Asia populations
for men only; and for prostate cancer the
association became negative in U.S. pop-
ulations (almost exclusively whites, RR
0.79, P = 0.001, I2 = 9%). This last ﬁgure
was also signiﬁcant if a mortality study
(dataset n = 69) was excluded (RR 0.75
[95% CI 0.60–0.94], P = 0.011, I2 =
0.0%).
We also examined mortality from
cancer in the available studies for which
we had at least two datasets (Table 2).
There were three cohort studies from
the U.S. (two for both sexes, one for
men only) and a case-control study from
China (both sexes) for colorectal cancer
only (8,9,16,20). Risk estimate for cancer
mortality was 1.61 (P, 0.0001), with no
heterogeneity (I2 = 0.0%).
We also examined whether results for
cancer association differed according to
whether studies of different design (case-
control and patient series) were included
in the full analysis (Table 2). For breast
cancer, the inclusion of two case-control
studies (26,27) with 3,950 cases pro-
duced a signiﬁcant overall association
(11 datasets, 9,643 cases) of 1.23 (P =
0.009) with high heterogeneity (88%).
For liver cancer, the inclusion of two large
case-control studies (29,30), with an
additional 4,951 cases, produced a signif-
icant association for women (RR 1.62,
P , 0.0001).
The deﬁnitions used for diagnosis of
metabolic syndrome affected estimates
of the association between metabolic
Figure 2dMeta-analyses for some common cancer sites in both sexes: colorectal and liver
cancer in men (A) and colorectal, breast postmenopausal, endometrial, and pancreatic cancer in
women (B). ES, effect size; MS, metabolic syndrome.
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syndrome and cancer risk (Table 2). For
both sexes, the estimates remained similar
for colorectal cancer (RR 1.33 and 1.22 for
traditional versus nontraditional deﬁni-
tions); for liver cancer, both deﬁnitions
achieved signiﬁcant associations (1.88
and 1.51); for pancreas cancer, there was
no association with traditional deﬁnitions
(RR 1.13, P = 0.745); for prostate cancer,
both deﬁnitions gave similar results; and
for breast cancer, there was an association
with traditional deﬁnitions only (1.45, P =
0.025).
To summarize the results for cohort
studies with available data (32 cohorts),
risk estimates for single factors were
equal to metabolic syndrome in 15
cohorts, higher in 11 cohorts, and lower
in 6 cohorts. For colorectal cancer, for
example, all increased cancer risk was
explained by diabetes alone (9,10),
diabetes and waist (10), diabetes
and BMI (12), and triglycerides .150
mg/dL (15); other single or combined
factors explained part (from 30 to
50%) of the increased risk conveyed by
metabolic syndrome: BMI (11,21), waist
(16,19), BMI and lipid (17), BMI
and dysglycemia (14), and hyperten-
sion (21).
Inﬂuence analysis showed that no
single study affected the sex-speciﬁc
summary estimates for most sites. More-
over, we did not note funnel plot asym-
metry for cancer sites where a sufﬁcient
number of datasets exited to run the
Egger test (colorectal cohorts men, P =
0.912; colorectal cohortswomen,P=0.201;
and prostate cancer cohorts, P = 0.085).
CONCLUSIONSdOur results from
meta-analyses of prospective cohort stud-
ies indicate that metabolic syndrome is
consistently associated with an increased
risk of several cancers in adults. However,
many of the reported associations are
small (RR between 1.1 and 1.6) andmight
differ between sexes for some sites and
also across populations. In particular, the
associations were stronger in women for
some cancers (pancreas and rectal), and
the magnitude of the associations was
highest for sex-speciﬁc cancers (endome-
trial and breast postmenopausal). More-
over, from analyses in which sufﬁcient
datasets existed, the association was
stronger for colorectal cancer in female
European populations (RR 1.64 [95%
CI 1.17–2.28]; ﬁve datasets with 2,665
incident cancers) and became protective
for prostate cancer in the white U.S. pop-
ulations, which needs conﬁrmation from
future studies. Given the widespread dif-
fusion of metabolic syndrome (1) and the
increased cancer mortality associated
with metabolic syndrome (2), the ﬁnd-
ings of the present meta-analysis may
have a clinical signiﬁcance. At least for
some common cancer sites (colorectal
cancer in both sexes, liver cancer in
men, and pancreas cancer in women),
we are conﬁdent that the results are
real, as the grading for study quality was
moderate to high and overall risk of bias
was low. Moreover, the inclusion of the
few case-control studies did not change
the overall estimates signiﬁcantly. In gen-
eral, the most robust association seems to
be with colorectal cancer in both sexes
and liver cancer in men. However, part
of the association may be explained by
the presence of obesity and overt hyper-
glycemia.
Mechanisms that link metabolic syn-
drome and cancer risk are not fully un-
derstood. Metabolic syndrome may be a
surrogate marker for other cancer risk
factors, such as decreased physical activ-
ity, consumption of high–calorie dense
foods, high dietary fat intake, low ﬁber
intake, and oxidative stress (1). Excess
adiposity, in particular visceral obesity,
results in a state of chronic systemic
low-grade inﬂammation, attributed to
Figure 2dContinued
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production of inﬂammatory cytokines by
both adipocytes and inﬁltrating immune
cells creating a protumorigenic environ-
ment (51). By contrast, adiponectin levels
are inversely associated with risk of some
cancer, and some polymorphisms of adi-
ponectin and its receptor genes are asso-
ciated with multiple cancer risk (52). The
altered balance between proinﬂamma-
tory and antiinﬂammatory cytokines
driven by central obesity might contrib-
ute to insulin resistance, a core compo-
nent of the metabolic syndrome. The
IGF-1 axis has also been implicated in
the progression of breast, pancreatic,
and esophageal cancer (53): levels of
IGF are inﬂuenced by circulating insulin
levels, with increasing insulin leading to
decreased levels of IGF-binding proteins
1 and 2, thus increasing the bioavailabil-
ity of IGF.
There were some limitations to this
meta-analysis. Although not suggested by
the formal statistical tests that we under-
took, there is still a possibility of publica-
tion bias considering that the tests were
likely to be underpowered. Moreover, we
cannot exclude the possibility of residual
confounding and bias because of misclas-
siﬁcation. Although the included studies
attempted to control for various known
risk factors, the possibility of residual or
unmeasured confounding cannot be ruled
out. Single-point measurement increases
the chance of random measurement error,
which may underestimate the reported
associations. Studies on the association
between metabolic syndrome and cancer
risk used different factors and cutoff points,
which complicate comparisons between
studies. Additionally, metabolic factors
were not directly measured in some co-
horts but replaced either by proxy indica-
tors of the factor (i.e., hypercholesterolemia
as a proxy indicator of high triglyceride
and/or low HDL cholesterol levels),
self-reported diagnosis of diseases
(i.e., diabetes, hypertension), or speciﬁc
drug use (antidiabetic, antihypertensive,
and antidyslipidemic). However, there
was a consistent positive association be-
tween studies, despite the use of different
deﬁnitions.
There were also strengths to this anal-
ysis. Our pooled estimates for the primary
end point were based on prospective anal-
yses with detailed adjustment for a wide
range of variables. We used uniform meth-
ods and subgroup analyses to better deﬁne
associations across cancer types between
sexes, populations, cancer subsites, and
deﬁnitions of metabolic syndrome. More-
over, this is the ﬁrst meta-analysis that
entailed a comprehensive search for all
studies that assessed association between
metabolic syndrome and cancer risk.
Findings from this meta-analysis,
which includes many recently published
studies, suggest that metabolic syndrome
is associated with increased risk of com-
mon cancers. The excess risk of cancer
conferred by metabolic syndrome is low
to moderate and in part explained by
accompanying obesity of hyperglycemia.
Nevertheless, the increasing prevalence of
metabolic syndrome worldwide and the
high incidence of some malignancies,
particularly colorectal and breast cancers,
imply that every yearmany cases of cancer
are attributable to metabolic syndrome.
Preventive strategies (primary prevention
and early detection of cancer) are urgently
needed, as has been suggested for patients
affected by fully developed diseases, such
as diabetes (54). Moreover, patients with
the metabolic syndrome, even in the ab-
sence of obesity or diabetes, should be
encouraged to undergo appropriate can-
cer screenings, at least for some more fre-
quently involved sites, as recommended
for all people of their age and sex. More
importantly, we need evidence of whether
effective interventions to reduce the prev-
alence of metabolic syndrome in adult
populations (55) will reduce cancer risk.
The formulation of public health strate-
gies based on sustained and bearable life-
style changes can hopefully obtain
signiﬁcant results in the ﬁght against can-
cer at the population level.
Figure 2dContinued
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Table 2dMain analyses and prespeciﬁed subgroup analyses for cancer sites
Groups Datasets
Identiﬁcation
of datasets
(Supplementary Table 1) Cases RR (95% CI) P I2 (%) P of I2 Model
Colorectal 1–38
Cohorts, men 12 5, 7, 10, 11, 17, 19, 21,
24, 26, 28, 30, 32
4,814 1.25 (1.19–1.32) 0.000 34.9 0.111 F
U.S. 2 5, 10 601 1.33 (1.11–1.59) 0.002 0.0 0.356 F
Europe 6 7, 11, 17, 24, 30, 32 3,960 1.26 (1.09–1.46) 0.002 47.7 0.089 R
Asia 4 19, 21, 26, 28 253 1.10 (0.80–1.51) 0.568 43 0.153 F
Cohorts, women 10 6, 12, 18, 20, 22, 25,
27, 29, 31, 33
3,045 1.34 (1.09–1.64) 0.006 59.6 0.008 R
U.S. 1 6 87 1.16 (0.60–2.20)
Europe 5 12, 18, 25, 31, 33 2,665 1.64 (1.17–2.28) 0.004 81 0.000 R
Asia 4 20, 22, 27, 29 293 1.02 (0.76–1.36) 0.911 0.0 0.979 F
Mortality, men
and women 6 1, 2, 3, 4, 23, 34 887 1.61 (1.28–2.01) 0.000 0.0 0.776 F
Colon men 6 8, 13, 19, 26, 30, 35 1,529 1.33 (1.02–1.73) 0.033 59.3 0.031 R
Colon women 5 14, 20, 27, 31, 36 1,035 1.29 (0.93–1.78) 0.128 62.3 0.031 R
Rectum men 6 9, 15, 21, 28, 32, 37 1,035 1.23 (1.00–1.52) 0.050 41.8 0.126 F
Rectum women 5 16, 22, 29, 33, 38 647 1.49 (1.13–1.97) 0.004 16.3 0.311 F
Traditional men and
women 14
5, 6, 19, 20, 21, 22, 26, 27, 28,
29, 30, 31, 32, 33 1,833 1.33 (1.10–1.62) 0.004 40.7 0.057 R
Nontraditional men
and women 8 7, 10, 11, 12, 17, 18, 24, 25 6,026 1.22 (1.18–1.34) 0.000 56.2 0.025 R
Breast 39–49
All datasets 11 39–49 9,643 1.23 (1.05–1.45) 0.009 88 0.000 R
Cohorts 9 39–47 5,693 1.14 (0.98–1.32) 0.088 86 0.000 R
U.S. 1 40 162 1.12 (0.78–1.62)
Europe 6 39, 42, 43, 44, 46, 47 5,334 1.09 (0.94–1.26) 0.258 88 0.000 R
Asia 2 41, 45 197 1.53 (0.45–5.21) 0.499 91 0.001 R
Cohorts,
postmenopausal 5 40, 44, 45a, 46, 47 1,290 1.56 (1.08–2.24) 0.017 88 0.000 R
U.S. 1 40 162 1.12 (0.78–1.62)
Europe 3 44, 46, 47 1,086 1.35 (0.95–1.91) 0.094 86 0.001 R
Asia 1 45a 42 6.73 (2.93–15.4)
Case/control 2 48, 49 3,950 1.80 (1.43–2.27) 0.000 0.0 0.383 F
Traditional 5 40, 41, 45, 46, 47 732 1.45 (1.04–2.00) 0.025 71 0.008 R
Nontraditional 4 39, 42, 43, 44 2,961 0.97 (0.86–1.10) 0.633 84 0.000 R
Hepatobiliary 50–63
Liver, all datasets, men
and women 14 50–63 5,580 1.60 (1.32–1.94) 0.000 78.7 0.000 R
Liver, all datasets, men 7 50, 54, 56, 57, 59, 60, 61 3,199 1.65 (1.34–2.03) 0.000 79.5 0.000 R
Liver, all datasets,
women 6 51, 55, 58, 59, 60, 61 1,758 1.62(1.23–2.15) 0.000 86.5 0.000 R
Liver cohorts, men 5 50, 54, 56, 57, 59 402 1.43 (1.23–1.65) 0.000 0.0 0.732 F
U.S. 1 56 18 1.62 (0.59–4.41)
Europe 2 50, 59 228 1.36 (1.16–1.60) 0.000 0.0 0.831 F
Asia 2 54, 57 156 1.81 (1.25–2.62) 0.002 0.0 0.816 F
Liver cohorts, women 4 51, 55, 58, 59 163 1.42 (0.80–2.52) 0.224 70.8 0.016 R
Europe 2 51, 59 76 1.01 (0.46–2.24) 0.973 64 0.095 R
Asia 2 55, 58 87 2.09 (0.69–6.37) 0.193 78 0.034 R
Traditional, men and
women 5 54, 55, 56, 57, 58 261 1.88 (1.41–2.52) 0.000 18.5 0.297 F
Nontraditional, men
and women 5 50, 51, 59, 60, 61 4,696 1.51 (1.16–1.98) 0.002 88.4 0.000 R
Continued on p. 2409
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